INTRODUCTION

Cerebral amyloid angiopathy (CAA) involves cerebrovascular pathology, which is caused by the progressive accumulation of amyloid-beta (Aβ) in the media and adventitia of the cortical and leptomeningeal vessels. Previous autopsy studies have shown that the prevalence of CAA in Alzheimer’s disease (AD) is 70% to 90%. CAA is principally characterized by restricted lobar microbleeds (MBs), which can be detected by gradient-echo T2* (GRE) and susceptibility-weighted imaging (SWI). We herein report on a 62-year-old man who presented with 8 years of memory impairment. The apolipoprotein E (APOE) genotype was ε4/ε4, and a brain GRE performed 28 months before death revealed mild atrophy and no MBs. At autopsy, the patient scored “A3, B3, C3” according to the National Institute on Aging-Alzheimer’s Association guidelines; the patient thus exhibited a high level of AD neuropathological changes. Furthermore, immunohistochemical staining for Aβ showed antibody accumulation and severe cerebral amyloid angiopathic changes in numerous vessels with amyloid deposits. Our case suggests that radiological CAA markers, such as cerebral microbleed (CMB) or cerebral superficial siderosis, may not suffice to detect amyloid angiopathy in cerebral vessels. CAA should therefore be considered as a combined pathology in APOE ε4 homozygotes with AD, even if such patients do not exhibit CMB on MRI.

Key Words: Alzheimer’s disease, cerebral amyloid angiopathy, pathology

CASE REPORT

A 62-year-old ambidextrous man visited our memory clinic.

Pathologically Confirmed Cerebral Amyloid Angiopathy with No Radiological Sign in a Patient with Early Onset Alzheimer’s Disease

Seung Joo Kim1, Youjeong Seo2, Hee Jin Kim1, Duk L. Na1, Sang Won Seo1, Yeshin Kim1,3, and Yeon-Lim Suh2

Departments of 1Neurology and 3Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; 3Department of Neurology, Kangwon National University Hospital, Kangwon National University College of Medicine, Chuncheon, Korea.
His memory began to decline at the age of 59 and gradually deteriorated thereafter. By the age of 61, his family had begun to notice that he had developed visuospatial dysfunction, personality changes, and abnormal behaviors. He further demonstrated impaired activities of daily living, such as carelessness concerning personal hygiene, poor judgement in urgent situations, and difficulty in the work place. He was an accountant with 18 years of education. No family history of dementia.

---

**Fig. 1.** Initial MRI taken 5 years before death. (A) Axial brain MRI fluid-attenuated inversion recovery image demonstrates minimal white matter hyperintensities in the periventricular white matter. (B) There was no abnormal signal on gradient-echo T2* image. MRI, magnetic resonance imaging.

**Fig. 2.** (A-C) Neuronal loss and gliosis in the entorhinal, frontal cortex, and basal nucleus stained by hematoxylin & eosin. (D) Hippocampus of granulovacuolar degeneration (arrows).
or other neurologic diseases were reported. Upon neurologic examination, he showed rigidity in the axial and right upper limb. Dressing apraxia, dyscalculia, and right-left disorientation were also observed. No other abnormal neurologic signs were evident. His Mini-Mental State Examination (MMSE) score was 19. With the exception of attention, detailed neuropsychological tests further revealed marked impairment in most domains. His apolipoprotein E (APOE) genotype was ε4/ε4. An axial fluid-attenuated inversion recovery (FLAIR) image on 3T brain magnetic resonance imaging (MRI) showed mild atrophy in the bilateral medial temporal and frontal lobes. Mild white matter hyperintensities (WMHs), rated according to the modified Fazekas scale, were found in FLAIR images (Fig. 1A). Gradient-echo T2* (GRE) images showed no abnormalities (Fig. 1B). These findings fulfilled the Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD. After the diagnosis was determined, the patient was prescribed an acetylcholinesterase inhibitor. His symptoms remained stable for the following 5 months, but declined sharply to a MMSE score of 3 at the age of 63. Although FLAIR images demonstrated more atrophy and moderate WMH than that observed in previous imaging, axial GRE images showed no signal loss. Pittsburgh compound B (PiB) positron emission tomography was positive, and PiB uptake was found in the bilateral frontal, lateral temporal, and parietal lobes. The patient was admitted to a hospital with pneumonia and died of aggravated pneumonia at 67 years. A postmortem autopsy was performed.

The postmortem examination revealed a decreased brain weight of 985 g (standard for age: 1360 g). The bilateral frontal, parietal, and temporal lobes featured significant atrophy. Hippocampal atrophy, pallor of the locus coeruleus and substantia

Fig. 3. (A) Diffuse Aβ deposition in the cerebellum and neocortex stained by immunohistochemistry leading to A3 (Thal phase 5). (B) Tau deposition was also found throughout the neocortex stained by immunohistochemistry leading to B3 (Braak and Braak stage VI). (C) Neuritic plaques by Bielschowsky silver stain in the frontal and temporal cortex were common, corresponding to CERAD criteria 3. (D) Accumulation of antibodies against Aβ presented in the thickened walls of leptomeningeal and cortical arteries (arrows), as well as arterioles, in immunohistochemical staining. (E) Numerous vessels with amyloid deposits were surrounded with inflammatory infiltration (arrow) in hematoxylin & eosin staining.
nigra, and moderate ventricular dilatation were also observed. The thalamus, basal ganglia, brain stem, and cerebellum were relatively well preserved. Pathologic examination was performed on 13 sections using routine hematoxylin & eosin (H&E) (Fig. 2). Luxol fast blue, Bielschowsky silver stain, and immunohistochemical (IHC) staining for Aβ (Biolegend; 4G8), phosphorylated tau (Thermo scientific; AT8), TAR DNA-binding Protein-43 (TDP-43) (Cosmo bio; polyclonal), neurofilament (Dako, 2F11), GFAP (Novocastra, GA5), and α-synuclein (Abcam; polyclonal) were performed according to the National Institute on Aging-Alzheimer’s Association (NIA-AA) guidelines for AD neuropathologic changes (ADNC).

The neuropathologic findings corresponded to A3 (Thal phase 5), B3 (Braak and Braak stage VI), and C3 (Consortium to Establish a Registry for Alzheimer’s Disease; CERAD score frequent), indicating a high level of ADNC (Fig. 3A-C). No evidence of TDP-43 expression or Lewy body pathology was seen. Additionally, amyloid angiopathy was identified throughout cerebral, cerebellar, and mid brain parenchyma, as well as in almost all leptomeningeal vessels in the cerebral cortex, cerebellum, and brain stem. These observations were rated as severe according to the scales by Olichney, et al. and Vonsattel, et al. Aβ IHC and H&E staining revealed amyloid angiopathy (Fig. 3D and E). Perivascular microhemorrhages were associated with parenchymal amyloid angiopathy. The final diagnosis was AD with amyloid angiopathy.

This patient provided written informed consent and the study was approved by the Institutional Review Board of Samsung Medical Center (2016-11-032-005).

**DISCUSSION**

This report describes a case of EOAD with severe CAA burden. The patient was an APOE ε4 homozygote, which rendered him prone to CAA pathology. However, the last MRI (Fig. 4), taken at 64 years of age and 28 months before death, did not reveal any CAA-related markers.

Several pathologies are related to CAA, including microatheroma, microaneurysm, and microhemorrhage. MBs detected by GRE images represent microhemorrhages that result from the collapse of a microaneurysm. Though the patient’s brain exhibited a severe CAA burden, MRI did not reveal any MB. Parameters of the MRI may account for this discrepancy. Thin-section susceptibility-weighted imaging (SWI) and a higher field strength may have detected cerebral microbleeds (CMB), a CAA-related marker, where the GRE proved insufficient. Another possible explanation may be underestimated CMB by MRI with respect to histopathology.

Our report has two limitations. Although we used the latest MRI, there was a 28-month gap between MRI and autopsy. Therefore, the GRE could not show the CMB and exact CAA burden at the time of death. Second, as aforementioned, SWI is more sensitive than GRE and might have detected CMB.

In conclusion, although CMB on MRI may indicate microhemorrhage in advanced CAA, CMB might not appear on brain imaging. CAA should be considered as a combined pathology in AD patients who are APOE ε4 homozygotes, even if CMB does not appear on MRI.

**ACKNOWLEDGEMENTS**

This research was supported by a grant funded by the Research of Korea Centers for Disease Control and Prevention (2017-ER6203-00).

**ORCID**

Seung Joo Kim https://orcid.org/0000-0001-9391-1767
Yeshin Kim https://orcid.org/0000-0002-4643-5478
Yeon-Lim Suh https://orcid.org/0000-0002-1171-0951
REFERENCES

1. Mendel TA, Wierzbka-Bobrowicz T, Lewandowska E, Stępień T, Szpak GM. The development of cerebral amyloid angiopathy in cerebral vessels. A review with illustrations based upon own investigated post mortem cases. Pol J Pathol 2013;64:260-7.

2. Attems J, Jellinger KA, Lintner F. Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol 2005;110:222-31.

3. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 1996;46:1592-6.

4. Piazza F, Greenberg SM, Savoiardo M, Gardinetti M, Chiapparini L, Raicher I, et al. Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol 2013;73:449-58.

5. DiFrancesco JC, Longoni M, Piazza F. Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer's disease and cerebral amyloid angiopathy. Front Neurol 2015;6:207.

6. Pantoni L, Basile AM, Pracucci G, Asplund K, Bogousslavsky J, Chabriat H, et al. Impact of age-related cerebral white matter changes on the transition to disability - the LADIS study: rationale, design and methodology. Neuroepidemiology 2005;24:51-62.

7. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-9.

8. Olichney JM, Hansen LA, Hofstetter CR, Grundman M, Katzman R, Thal LJ. Cerebral infarction in Alzheimer’s disease is associated with severe amyloid angiopathy and hypertension. Arch Neurol 1995;52:702-8.

9. Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP Jr. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 1991;30:637-49.

10. Ringman JM, Sachs MC, Zhou Y, Monsell SE, Saver JL, Vinters HV. Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically verified Alzheimer disease. JAMA Neurol 2014;71:878-83.

11. Nandigam RN, Viswanathan A, Delgado P, Skehan ME, Smith EE, Rosand J, et al. MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength. AJNR Am J Neuroradiol 2009;30:338-43.

12. Haller S, Montandon ML, Lazeyras F, Scheffler M, Meckel S, Hermann FR, et al. Radiologic-histopathologic correlation of cerebral microbleeds using pre-mortem and post-mortem MRI. PLoS One 2016;11:e0167743.